Global Preimplantation Genetic Diagnosis (PGD) Testing Market US$ 125 Million by 2021

Global Preimplantation Genetic Diagnosis (PGD) Testing Market US$ 125 Million by 2021

According to a market research report published by iHealthcareAnalyst, Inc., Preimplantation Genetic Diagnosis Testing Market – Global Diagnostic Applications and End Users Analysis and Forecast 2017-2021, the global Preimplantation genetic diagnosis testing market was valued at US$ 78 Million in 2015 and is estimated to reach US$ 116 Million by 2021, at a CAGR of 8.3% from 2017 to 2021.

Browse the Preimplantation Genetic Diagnosis Testing Market – Global Diagnostic Applications and End Users Analysis and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/preimplantation-genetic-diagnosis-market/

Preimplantation genetic diagnosis (PGD or PIGD) is used to identify genetic defects in embryos created through in vitro fertilization (IVF) before pregnancy and can test for more than 100 different genetic conditions. PGD is available for a large number of monogenic disorders such as single gene disorders (autosomal recessive, autosomal dominant or X-linked) or chromosomal structural aberrations (such as a balanced translocation). The Preimplantation genetic diagnosis testing market report estimates the market size (Revenue US$ million – 2014 to 2021) for market segmentation based on diagnostic test type (aneuploidy screening, chromosomal aberrations, gender selection, HLA typing, single gene disorders, X-linked diseases, etc.), and forecasts growth trends (CAGR% – 2017 to 2021). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

The global Preimplantation genetic diagnosis testing market is segmented as:

  1. Diagnostic Test Type
    • Aneuploidy Screening
    • Chromosomal Aberrations
    • Gender Selection
    • Human Leukocyte Antigen (HLA) Typing
    • Single Gene Disorder
    • X-linked Diseases
  1. End User
    • Hospitals
    • PGD Centers
    • Diagnostic Laboratories
    • Others
  1. Geography (Region, Country)
    • North America (U.S., Canada)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World
  1. Company Profiles
    • Genea Ltd.
    • Genesis Genetics
    • Illumina, Inc.
    • Laboratory Corporation of America Holdings (LabCorp)
    • Natera, Inc.
    • PerkinElmer, Inc.
    • Quest Diagnostics, Inc.
    • Reproductive Genetics Institute
    • Reprogenetics LLC

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: [email protected]
Website: https://www.ihealthcareanalyst.com

2017-11-05T11:21:53+00:00 Categories: Press Releases|